Literature DB >> 7594784

[Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster].

K Terada1, Y Hiraga, S Kawano, N Kataoka.   

Abstract

We found that pediatricians have enhanced specific cellular immunity to varicella-zoster virus (VZV) compared with the general population, which may be due to reexposure to VZV from children with chickenpox. There have been some reported that the varicella vaccine enhance the specific cellular immunity. To estimate the efficacy of varicella vaccine for protection against herpes zoster in the elderly, we investigated the incidence of herpes zoster in 500 pediatricians and family practitioners with their fifties and sixties, and history of reexposure to VZV in 61 patients with herpes zoster by questionnaires retrospectively. Thirty-four of 352 pediatricians had a past history of herpes zoster. The incidence per 100,000 person-years of herpes zoster was 65.2 in those in their fifties and 158.2 in those in their sixties, which are 1/2 to 1/8 of other reports regarding the general population. Among 61 immunocompetent patients with herpes zoster, only 4 patients (6.6%) had the chance for reexpose to VZV before their herpes zoster. Only 7 (17.5%) of the 40 patients older than 50 years of age lived with their children less than 14 years of age. Twenty-three (57.5%) of them lived without their children and grandchildren. They are thought to be less chance to reexpose to VZV through children. We may think that the booster effect by reexposure to VZV plays an important role to prevent herpes zoster. Therefore, we can speculate that the varicella vaccine may protect against herpes zoster in the elderly by the enhanced specific cellular immunity due to the booster effect.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594784     DOI: 10.11150/kansenshogakuzasshi1970.69.908

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  6 in total

Review 1.  Chickenpox, chickenpox vaccination, and shingles.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  2006-05       Impact factor: 2.401

2.  Herpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination.

Authors:  James G Donahue; Burney A Kieke; Paul M Gargiullo; Aisha O Jumaan; Nicholas R Berger; Jeremy S McCauley; Edward A Belongia
Journal:  Am J Public Health       Date:  2010-01-14       Impact factor: 9.308

3.  Varicella vaccination in Europe: are we ready for a universal childhood programme?

Authors:  Nitu Sengupta; Robert Booy; H J Schmitt; Heikki Peltola; Pierre Van-Damme; R Fabian Schumacher; Magda Campins; Carlos Rodrigo; Terho Heikkinen; Jane Seward; Aisha Jumaan; Adam Finn; Per Olcén; Nancy Thiry; Catherine Weil-Olivier; Judith Breuer
Journal:  Eur J Pediatr       Date:  2007-03-03       Impact factor: 3.860

Review 4.  Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.

Authors:  G S Goldman; P G King
Journal:  Vaccine       Date:  2012-06-01       Impact factor: 3.641

Review 5.  Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.

Authors:  Kunihiro Yamaoka
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228

6.  Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.

Authors:  G S Goldman; P G King
Journal:  Hum Exp Toxicol       Date:  2013-11-25       Impact factor: 2.903

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.